CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 723,032 shares of the company’s stock after selling 1,209 shares during the period. Charles Schwab Investment Management Inc.’s holdings in CRISPR Therapeutics were worth $28,459,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Finally, Spire Wealth Management increased its position in CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock worth $78,000 after purchasing an additional 1,482 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at $350,516.46. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,381 shares of company stock valued at $1,608,243. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CRSP shares. Truist Financial boosted their target price on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Morgan Stanley boosted their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research note on Friday, February 14th. Chardan Capital decreased their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Barclays boosted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Citigroup decreased their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Up 1.7 %

CRISPR Therapeutics stock opened at $42.82 on Tuesday. The company’s fifty day simple moving average is $43.06 and its 200-day simple moving average is $45.51. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $75.91. The stock has a market cap of $3.67 billion, a P/E ratio of -9.80 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.